Pharmaceuticals
111, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results
SHANGHAI, March 17, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the fourth qua...
2022-03-17 15:20
2699
Korea Health Industry Development Institute operates Korean Pavilion at 'HIMSS Global Health Conference & Exhibition'
- Presenting the latest healthcare technologies with leading innovation companies ofSouth Korea ORLANDO, Fla., March 15, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) announced its operation of the Korean pavilion at the 2022 HIMSS Global Health Conference& Exhibition ...
2022-03-16 06:44
2288
United Imaging Receives Contract from Vizient for its X-ray and Magnetic Resonance Imaging Systems
HOUSTON, March 15, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received a contract from Vizient, Inc., for its entire portfolio of DR (X-Ray) and MR (magnetic resonance) systems. The contract expands the number of modalities off...
2022-03-15 21:00
2274
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provides updates on the recent development relating ...
2022-03-15 20:00
2023
Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Mar. 14, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has dosed the first patient in the pivota...
2022-03-15 14:52
2053
I Peace triples GMP cell manufacturing by expanding CDMO facility
PALO ALTO, Calif., March 14, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility.The facility's expansion, ...
2022-03-15 03:22
1851
Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs
NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 14, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, is pleased to welcome new senior level talent to its dynamic global leadership team.V...
2022-03-15 02:00
2376
MediLink Therapeutics closes US$70 million Series B financing
SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of aUS$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highligh...
2022-03-14 20:50
2702
NuclixBio Announces a Collaborative Research Agreement with PharmAbcine
SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech...
2022-03-14 20:00
2525
111, Inc. Becomes First Online Retail Platform for BGI's SARS-CoV-2 Virus Antigen Detection Kits
SHANGHAI, March 14, 2022 /PRNewswire/ -- On March 14, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company signed a strategic cooperation agreement with Shenzhen BGI Co., Ltd. (SZ: 300676) under which BGI will supply its SARS-CoV-2 Virus Ant...
2022-03-14 19:35
2186
Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study
SHANGHAI, March 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the Hainan Provincial Medical Products...
2022-03-14 14:25
1859
Impact Therapeutics Announces Completion of Series D1 Financing
SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that par...
2022-03-14 12:43
2334
THE WORLD'S FIRST ACADEMIC PAPER ON THE POTENTIAL USE OF VIRTUAL REALITY IN MODULATING PSYCHEDELIC-ASSISTED PSYCHOTHERAPY PUBLISHED BY THE CO-FOUNDERS OF ENOSIS THERAPEUTICS
The Peer-Reviewed Article Published In Volume 13 March 2022 Issue Of Frontiers In Psychology Journal Is A Landmark Examination Of Virtual Reality Therapy Combined With Psychedelic Therapy. MELBOURNE, Australia, March 10, 2022 /PRNewswire/ -- The world's first scientific paper offering a careful...
2022-03-10 21:00
1997
Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting
* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinical data suggests that BBT-207 may have the potential to be positioned as a frontline treatment with the anti-tumor effects in EGFR mutant NSCLC SEONGNAM, South Korea, March 9, 2022 /PRNewswire/ -- B...
2022-03-10 07:00
2087
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational r...
2022-03-09 21:00
2113
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of t...
2022-03-09 07:47
3864
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
SEATTLE, Wash. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- ProfoundBio announced that preclinical data from its pipeline of novel, proprietary antibody-drug conjugates (ADCs) and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held Apr...
2022-03-09 06:58
4968
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the IND...
2022-03-08 11:49
2165
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients
SUZHOU, China, March 6, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its...
2022-03-07 08:18
3726
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
* Phase 2 study of PVX108 to commence in United States and Australia * Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology compa...
2022-03-04 21:00
3399
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 321 media titles]
2026-02-19 14:30
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 301 media titles]
2026-02-23 08:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 280 media titles]
2026-02-17 19:12
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 279 media titles]
2026-02-23 10:09
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 259 media titles]
2026-02-17 14:16